VIVE Vivesto AB (publ)
Vivesto AB (publ) develops, develops, markets, and sells drugs in the field of human and veterinary oncology in Sweden. Its lead product, Paccal Vet, is a formulation of paclitaxel with its XR-17 encapsulation technology for the treatment of canine mastocytoma. The company also provides Apealea, an injectable formulation of paclitaxel for the treatment of various cancers. In addition, it develops Cantrixil, a drug candidate for the treatment of advanced cancer, and Docetaxel micellar for the treatment of prostate cancer. The company was formerly known as Oasmia Pharmaceutical AB (publ) and changed its name to Vivesto AB (publ) in March 2022. Vivesto AB (publ) was founded in 1988 and is headquartered in Solna, Sweden.…
Industry Peers
Drug Manufacturers - Specialty & GenericKey Statistics
About Vivesto (STO: VIVE)
›
Vivesto (STO: VIVE) is listed on Nasdaq Stockholm, where its shares trade in SEK. It belongs to the Drug Manufacturers - Specialty & Generic industry, part of the Healthcare sector, and reports about 4 employees.
The shares were at 7.250 SEK on 19 November 2026, down 65.1% over 52 weeks. Its 52-week range is 6.500 SEK to 23.76 SEK: the price is 69.5% below the high and 11.5% above the low.
Its market capitalisation is 80.27M SEK.
Vivesto reports return on equity of -27.4%.
It holds more cash than debt, a net cash position of 16.76M SEK. Its Piotroski F-score is 3 out of 9, a weak reading of its financial health. One analyst covers the stock; their mean price target of 18.50 SEK is 155.2% above the current price. The next earnings report is expected on 11 February 2027.